Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Clinical trial NCT05923190 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05923190
- Sponsor
- Fox Chase Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-14
- Primary completion
- 2028-07-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.